Disrupting CXCL12 from CAFs enhances T cell-mediated tumor control, and targeting focal adhesion kinase (FAK) in cancer cells simultaneously reduces stromal fibroblast activation and the formation of an immunosuppressive milieu (120). Here, CXCL12 is linked to cancer.